Recruiting
Phase 2

D-2570

Sponsor:

InventisBio Co., Ltd

Code:

NCT07489885

Conditions

Psoriasis

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

D-2570 Tablet

Placebo Tablets

Study Details

Brief summary:

A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis

Conditions

Psoriasis

Study ID

NCT07489885

Start date

Jun 3, 2026

Status verified date

Mar, 2026

Completion date

Dec, 2027

Anticipated

Primary completion date

Aug, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participants with a diagnosis of plaque psoriasis with no significant flares of disease activity for at least 6 months before signing the informed consent
  • Participants have moderate to severe plaque psoriasis as defined by a total body surface area (BSA) ≥10%, a Psoriasis Area and Severity Index (PASI) score ≥ 12 and a Physician's Global Assessment (PGA) score ≥ 3.
  • Within normal ranges of laboratory assessments

Exclusion Criteria:

  • Any comorbidities or past medical conditions as outlined in the protocol that would interfere with study assessments as deemed by the Investigator

Study Design

Enrollment

75 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: D-2570 low dose

Low dose of D-2570

active comparator: D-2570 High Dose

medium dose level of D-2570

placebo comparator: Placebo

Placebo arm

Interventions

D-2570 Tablet

Active Treatment

Placebo Tablets

Identical Tablet

Primary outcome measure

  • Improvement in PASI-90 [ Time Frame: Assessment completed after 12 weeks of treatment/placebo ]

Central Contacts and Locations

Central contacts

Kathryn Stazzone

3025195966kathryn.stazzone@inventisbio.com

Locations

Study Center

Recruiting

Birmingham, Alabama, United States, 35244

Contacts

Kathryn Stazzone

302-519-5966kathryn.stazzone@inventisbio.com

Study Center

Recruiting

Chula Vista, California, United States, 91910

Contacts

Kathryn Stazzone

302-519-5966kathryn.stazzone@inventisbio.com

Study Center

Recruiting

San Antonio, Texas, United States, 78218

Contacts

Kathryn Stazzone

302-519-5966kathryn.stazzone@inventisbio.com

More Information

Sponsor

InventisBio Co., Ltd

Last update posted

Jul 9, 2026

Last verified

Mar, 2026

Keywords

  • Moderate to Severe Plaque Psoriasis

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by InventisBio Co., Ltd on 2026-07-09.